Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions recommendations and rationale

American Family Physician

Volumn 67, Issue 2, 2003, Pages 358-364

  Berg, Alfred O ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE;

ALERTNESS; BREAST CARCINOMA; CANCER RISK; CHOLECYSTITIS; COGNITION; DEEP VEIN THROMBOSIS; DEMENTIA; ENDOMETRIUM CARCINOMA; EPIDEMIOLOGICAL DATA; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FRACTURE; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; INFORMATION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; MORBIDITY; MOTOR PERFORMANCE; OSTEOPOROSIS; OVARY CARCINOMA; REVIEW; RISK; STROKE; VERBAL MEMORY;

AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COLORECTAL NEOPLASMS; DEMENTIA; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 0037437905     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996.
2. Nelson HD, Humphrey LL, LeBlanc E, Miller J, Takano L, Chan BK, et al. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions: a summary of the evidence for the U.S. Preventive Services Task Force. Rockville, Md.: Agency for Healthcare Research and Quality, 2002. Accessed December 2002 at: www.ahrq.gov/clinic/3rduspstf/hrt/hrtsum3.htm.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
4. Grady D, Rubin SM, Petitti D, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
5. Cancer facts & figures 2002. Colorectal cancer and early detection. American Cancer Society. Accessed December 2002 at: www. cancer.org/downloads/STT/CancerFacts&Figures2002TM.pdf.
6. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-7.
7. Hulley, S, Furberg C, Barrett-Conner E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
8. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.
9. Leblanc E, Chan B, Nelson HD. Hormone replacement therapy and cognition. Systematic Evidence Review No. 13 (Prepared by the Oregon Health & Science Evidence-based Practice Center under Contract No. 290-97-0018). Accessed December 2002 at: www.ahrq.gov/clinic/serfiles.htm.
10. Steinberg KK, Smith SJ, Thacker SB, Stroup DE Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994;5:415-21.
11. Humphrey LL. Hormone replacement therapy and breast cancer. Systematic Evidence Review No. 14 (Prepared by the Oregon Health & Science Evidence-based Practice Center under Contract No. 290-97-0018). Accessed December 2002 at: www.ahrq.gov/clinic/serfiles.htm.
12. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
13. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973-80.
14. Humphrey LL, Takano LM, Chan BK. Hormone replacement therapy and cardiovascular disease. Systematic Evidence Review No. 10 (Prepared by the Oregon Health & Science Evidence-based Practice Center under Contract No. 290-97-0018). Accessed December 2002 at: www.ahrq.gov/clinic/serfiles.htm.
15. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
16. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-42.
17. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.
18. Miller J, Chan BK, Nelson H. Hormone replacement therapy and risk of venous thromboembolism. Systematic Evidence Review No. 11 (Prepared by the Oregon Health & Science Evidence-based Practice Center under contract No. 290-97-0018). Accessed December 2002 at: www.ahrq.gov/clinic/serfiles.htm.
19. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:680-90.
20. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
21. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Harthe P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-41.
22. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-5.
23. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32.
24. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994;83:5-11.
25. Simon JA, Hunninghake DB, Agarwal SK, Lin F, Cauley JA, Ireland CC, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001;135:493-501.
26. Questions and answers on hormone therapy. The American College of Obstetricians and Gynecologists. Accessed December 2002 at: www.acog.org/from_home/publications/press_releases/ nr08-30-02.cfm.
27. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. The North American Menopause Society. Accessed December 2002 at: www.menopause.org/news.html# advisory.
28. Q & A about hormone replacement therapy. American Heart Association. Accessed December 2002 at: http://216.185.112.5/presenter.jhtml?identifier=3004068.
29. Nawaz H, Katz DL. American College of Preventive Medicine practice policy statement: perimenopausal and postmenopausal hormone replacement therapy. Am J Prev Med 1999;17:250-4.
30. AACE medical guidelines for clinical practice for management of menopause. The American Association of Clinical Endocrinologists. Endocr Pract 1999;5:354-66.
31. American Academy of Family Physicians. Periodic health examinations. Strongly recommend: general population. Accessed December 2002 at: www.aafp.org/x10600.xml.
32. Canadian Task Force on Preventive Health Care. Reviews in progress. Accessed December 2002 at: www.ctfphc.org/index.html.